SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.

K H Chow, Pierce; Gandhi, Mihir; Tan, Say-Beng; Win Khin, Maung; Khasbazar, Ariunaa; Ong, Janus; Pin Choo, Su; Chung Cheow, Peng; Chotipanich, Chanisa; Lim, Kieron; A Lesmana, Laurentius; W Manuaba, Tjakra; Koon Yoong, Boon; Raj, Aloysius; Soon Law, Chiong; H Y Cua, Ian; R Lobo, Rolley; S C Teh, Catherine; Hwan Kim, Yun; Won Jong, Yun; Han, Ho-Seong; Bae, Si-Hyun; Yoon, Hyun-Ki; Lee, Rheun-Chuan; Hung, Chien-Fu; Peng, Cheng-Yuan; Liang, Po-Chin; Bartlett, Adam; Y Y Kok, Kenneth; Thng, Choon-Hua; Su-Chong Low, Albert; S W Goh, Anthony; Hiong Tay, Kiang; H G Lo, Richard; K P Goh, Brian; C E Ng, David; Lekurwale, Ganesh; Ming Liew, Wei; Gebski, Val; S W Mak, Kenneth; Chee Soo, Khee; Hepatocellular Carcinoma Trials Group, Asia-Pacific

doi:10.1200/jco.2017.76.0892

Public

SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.

Published in Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Jul 1, 2018

NobleIDark:/48914/w1/20260526/AC695AC2Record on NobleID

Authors:

Pierce K H Chow

,

Mihir Gandhi

,

Say-Beng Tan

Abstract

Purpose Selective internal radiation therapy or radioembolization (RE) shows efficacy in unresectable hepatocellular carcinoma (HCC) limited to the liver. This study compared the safety and efficacy of RE and sorafenib in patients with locally advanced HCC. Patients and Methods SIRveNIB (selective i...

Discussions